MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update
2024年2月22日 - 9:00PM
ビジネスワイヤ(英語)
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED)
(the “Company” or “MindMed”), a clinical stage biopharmaceutical
company developing novel product candidates to treat brain health
disorders, announced today that it plans to host a conference call
on Wednesday, February 28, 2024, at 8:00 a.m. ET to provide a
corporate update and review the Company’s results for the year
ended December 31, 2023.
Listeners can register for the webcast via this link. Analysts
wishing to participate in the question and answer session should
use this link. A replay of the webcast will be available via the
Investor Relations section of the MindMed website,
https://ir.mindmed.co/, and archived for at least 30 days after the
webcast. Those who plan on participating are advised to join 15
minutes prior to the start time.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative drug
candidates, with and without acute perceptual effects, targeting
the serotonin, dopamine, and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Cboe
Canada exchange (formerly the NEO Exchange) under the symbol
MMED.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240222042904/en/
For Media: media@mindmed.co For Investors:
ir@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
過去 株価チャート
から 4 2024 まで 5 2024
Mind Medicine MindMed (NASDAQ:MNMD)
過去 株価チャート
から 5 2023 まで 5 2024